Search strategy
We searched CENTRAL, MEDLINE, EMBASE, CINAHL and PEDro up to 5 August 2008, checked conference proceedings and reference lists, and contacted authors.
Selection criteria
Randomised or quasi-randomised controlled trials that compared SAMe at any dosage and in any formulation with placebo or no intervention in patients with osteoarthritis of the knee or hip.
Data collection and analysis
Two independent authors extracted data using standardised forms. We contacted investigators to obtain missing outcome information. We calculated standardised mean differences (SMDs) for pain and function, and relative risks for safety outcomes. We combined trials using inverse-variance random-effects meta-analysis.
Main results
Four trials including 656 patients were included in the systematic review, all compared SAMe with placebo. The methodological quality and the quality of reporting were poor. For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I 2 = 0). For function, the analysis suggested a SMD of 0.02 (95% CI -0.68 to 0.71) with a moderate degree of between-trial heterogeneity (I2 = 54%). The meta-analyses of the number of patients experiencing any adverse event, and withdrawals or drop-outs due to adverse events, resulted in relative risks of 1.27 (95% CI 0.94 to 1.71) and 0.94 (95% CI 0.48 to 1.86), respectively, but confidence intervals were wide and tests for overall effect were not significant. No trial provided information concerning the occurrence of serious adverse events.
Authors' conclusions
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality. The effects of SAMe on both pain and function may be potentially clinically relevant and, although effects are expected to be small, deserve further clinical evaluation in adequately sized randomised, parallel-group trials in patients with knee or hip osteoarthritis. Meanwhile, routine use of SAMe should not be advised.
P L A I N L A N G U A G E S U M M A R Y

S-Adenosylmethionine (SAMe) for osteoarthritis
This summary of a Cochrane review presents what we know from research about the effect of S-Adenosylmethionine on osteoarthritis.
The review shows that in people with osteoarthritis:
-We are uncertain whether S-Adenosylmethionine affects pain or your ability to use your knee because of the low to moderate quality of the evidence.
-S-Adenosylmethionine may not have any side effects. We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects.
What is osteoarthritis and what is S-Adenosylmethionine (SAMe)?
Osteoarthritis (OA) is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try to repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
S-Adenosylmethionine is popular dietary supplement available over the counter in drug stores or health food stores. It is also a naturally occurring chemical that is produced in the body. SAMe is not found in foods, so it must be taken as a supplement.
Best estimate of what happens to people with osteoarthritis who take S-Adenosylmethionine (SAMe)
Pain -People with S-Adenosylmethionine and people with placebo are equally likely to respond to treatment (difference of 0%). This could be the result of chance.
-People who took S-Adenosylmethionine had an improvement in their pain of about 2 on a scale from 0 (no pain) to 10 (extreme pain) after using it up to 3 months.
-People who took a placebo had an improvement in their pain of also about 2 on a scale from 0 (no pain) to 10 (extreme pain) after using it up to 3 months.
Physical Function
-People with S-Adenosylmethionine and people with placebo are equally likely to respond to treatment (difference of 0%). This could be the result of chance.
-People who took S-Adenosylmethionine had an improvement in their physical function of about 1 on a scale of 0 (no disability) to 10 (extreme disability) after using it up to 3 months.
-People who took a placebo had an improvement in their physical function of also about 1 on a scale of 0 (no disability) to 10 (extreme disability) after using it up to 3 months.
Side effects
-4 more people experienced side effects with S-Adenosylmethionine than with placebo (difference of 4%). This could be the result of chance.
-19 people out of 100 who used S-Adenosylmethionine experienced side effects (19%).
-15 people out of 100 who used a placebo experienced side effects (15%).
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [ Explanation]
S-Adenosylmethionine compared with placebo or no intervention for osteoarthritis of the knee or hip Patient or population: Patients with osteoarthritis of the knee or hip Settings: Outpatient clinic of either rheumatologic, orthopedic or veteran's hospital departments Intervention: S-Adenosylmethionine Comparison: Placebo or no intervention
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI) 2 Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical pooled SD of 2.5 cm in trials that assessed pain using a VAS, and expressed as change based on an assumed standardised reduction of 0.72 standard deviation units in the control group. 3 The median observed pain score at baseline across control groups in large osteoarthritis trials was 6.1 cm on a 10 cm VAS (Nüesch 2009). 4 Downgraded (1 level) because analyses was not according to intention-to-treat principle, 2 out of 4 trials reported this outcome, potentially leading to selective outcome reporting bias, 1 out of 2 trials used adequate, 1 used unclear concealment of allocation methods, possible indirectness of evidence (indirect population) in 1 out of 2 studies. 5 Standardised mean differences (SMDs) were back-transformed onto a 0 to 10 standardised WOMAC function score on the basis of a typical pooled SD of 2.1 in trials that assessed function on WOMAC function scale and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group. 6 The median observed standardised WOMAC function score at baseline across control groups in large osteoarthritis trials was 5.6 units (Nüesch 2009). 7 Downgraded (2 levels) because: analyses was not according to intention-to-treat principle, presence of moderate between-trial heterogeneity, possible indirectness of evidence (indirect population) in 2 out of 3 studies, the confidence interval is wide and crossed no difference, 1 out of 3 trials used adequate, 2 used unclear concealment of allocation methods. 8 Downgraded (1 level) because the confidence interval crosses no difference, in 1 out of 4 trials analyses was not according to intentionto-treat principle. 9 Downgraded (1 level) because the confidence interval is wide and crossed no difference.
No of Participants (studies)
Quality of the evidence (GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no intervention S-Adenosylmethionine
B A C K G R O U N D
Osteoarthritis is a degenerative disease characterised by focal areas of loss of articular cartilage in synovial joints, subchondral bone changes, osteophyte formation at the joint margins, thickening of the joint capsule and mild synovitis (Altman 1996). Symptoms include pain, stiffness and decreased range of motion, limiting daily activities and reducing quality of life. To manage the symptoms of osteoarthritis, patients and healthcare providers often resort to multiple approaches, including lifestyle modifications, medications, exercise or surgery. Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of management for osteoarthritic pain, but may cause serious gastrointestinal and cardiovascular adverse events.
Beneficial effects of the dietary supplement S-Adenosylmethionine (SAMe) have been intensively advertised. Within a few years the supplement has become popular, surrounded by countless claims concerning its effectiveness with fewer side effects. SAMe is proposed for use as an antidepressant, a medication for cholestasis and liver disorders, a treatment for migraines, and therapy for fibromyalgia and osteoarthritis. The rationale for a general therapeutic application of SAMe stems from the hypothesis that subnormal biologically active levels of this substance will be normalised by a parenteral or peroral administration in a variety of organ systems. SAMe is deemed to induce beneficial changes in the individual, whose problems -at least in part -are related to a relative deficiency of the compound (Fetrow 2001). In osteoarthritis, the exact mechanism remains controversial. It is suggested that there is a mismatch between generative and degenerative forces that govern cartilage formation, partly because of a malfunction in proteoglycan synthesis. One in vitro study of SAMe (Harmand 1987) suggested that it may favourably affect the synthesis of proteoglycans. Additional mechanisms of SAMe in reducing pain in osteoarthritis include a reduction of inflammation and direct analgesic effects at central or peripheral levels, potentially mediated through a cyclo-oxygenase inhibition.
Initial studies with SAMe used the parenteral route exclusively due to the instability of the oral form. As additional work allowed the development of a stable oral form of SAMe, further studies tested the effectiveness of the oral form in the management of several medical conditions including osteoarthritis. . Similar conclusions were drawn in these reviews: that the results of the available studies were heterogeneous and did not allow firm claims to be made about the effectiveness of SAMe in the management of osteoarthritis.
O B J E C T I V E S
We set out to compare S-Adenosylmethionine (SAMe) with placebo or no specific intervention in terms of effects on pain and function and safety outcomes in patients with knee or hip osteoarthritis and to explore whether potential variation between trials could be explained by biases affecting individual trials or by publication bias.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials were eligible. Trials using an unpredictable allocation sequence were considered as randomised.
Types of participants
Trials including at least 75% of patients with clinically and/or radiologically confirmed osteoarthritis of the knee or hip. We excluded trials which evaluated SAMe after knee or hip surgery.
Types of interventions
We considered trials involving administration of S-Adenosylmethionine at any dosage and in any formulation. Eligible control interventions were placebo or a non-intervention control (usual care).
Types of outcome measures
Main outcomes
Main outcomes were pain and function, as currently recommended for osteoarthritis trials (Altman 1996; Pham 2004). If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (Jüni 2006; Reichenbach 2007) and extracted data on the pain scale that is highest on this list: 1. Global pain 2. Pain on walking 3. WOMAC osteoarthritis index pain subscore 4. Composite pain scores other than WOMAC 5. Pain on activities other than walking 6. Rest pain or pain during the night 7. WOMAC global algofunctional score 8. Lequesne osteoarthritis index global score 9. Other algofunctional scale 10. Patient's global assessment 11. Physician's global assessment If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy presented below.
1. Global disability score 2. Walking disability 3. WOMAC disability subscore 4. Composite disability scores other than WOMAC 5. Disability other than walking 6. WOMAC global scale 7. Lequesne osteoarthritis index global score 8. Other algofunctional scale 9. Patient's global assessment 10. Physician's global assessment If pain or function outcomes were reported at several time points, we extracted the measure at the end of the treatment period.
Secondary outcomes
Secondary outcomes included the number of patients experiencing any adverse event, patients who were withdrawn or dropped out because of adverse events, and patients experiencing any serious adverse events. We extracted end of trial data for these outcomes. We defined serious adverse events as events resulting in in-patient hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality/birth defect of offspring, life-threatening events or death.
Search methods for identification of studies Electronic searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, issue 3), MED-LINE (1966 to 5 August 2008) and EMBASE (1975 to 5 August 2008) through the Ovid platform ( www.ovid.com), and CINAHL (1937 to 5 August 2008) through EBSCOhost, using truncated variations of preparation names, including brand names, combined with truncated variations of terms related to osteoarthritis, as well as MESH headings. We applied a validated methodological filter for controlled clinical trials (Dickersin 1994). The specific search algorithms are displayed in Appendix 1 for MED-LINE, EMBASE and CINAHL, and in Appendix 2 for CEN-TRAL.
Searching other resources
We manually searched conference proceedings. We used Science Citation Index to retrieve reports citing the relevant articles. We screened reference lists of all obtained articles, including related reviews. We contacted content experts and trialists and asked them for relevant references. Finally, we searched several clinical trial registries ( www.clinicaltrials.gov, www.controlled-trials.com, www.actr.org.au, www.umin.ac.jp/ ctr) to identify ongoing trials. The last update of the manual search was on 28 July 2008.
Data collection and analysis
Selection of studies
Two review authors (AR and EN) independently evaluated all yielded titles and abstracts for eligibility (see Figure 1 ). We resolved disagreements by discussion. We applied no language restrictions. In case of multiple reports relating to the same trial, we considered all reports.
Figure 1. Study flow chart
Data extraction and management
Two review authors (AR and SR or EN) independently extracted trial information using a standardised, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion. We extracted the generic and the trade name of SAMe, the type of control used, dosage, frequency and duration of treatment, patient characteristics (average age, gender, mean duration of symptoms, type of joints affected), type of pain-and functionrelated outcome extracted, trial design, trial size, duration of follow up, type and source of financial support and publication status from trial reports. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross-over trials, we extracted data from the first period only because of possible carry-over effects. Whenever possible, we used results from an intention-to-treat analysis. If effect sizes could not be calculated, we contacted the authors for additional data.
Assessment of risk of bias in included studies
Two review authors (AR and SR or EN) independently assessed randomisation, blinding and adequacy of analyses (Jüni 2001). We resolved disagreements by consensus. We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. The generation was considered adequate if it resulted in unpredictable allocation sequences; mechanisms considered adequate include random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling of cards and drawing of lots. Trials using an unpredictable allocation sequence were considered randomised; trials using potentially predictable allocation mechanisms, such as alternation or the allocation of patients according to date of birth, were considered quasirandomised. We considered allocation concealment adequate if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next; methods considered adequate include central randomisation, pharmacy controlled randomisation using identical pre-numbered containers, and sequentially numbered, sealed, opaque envelopes. We considered blinding of patients adequate if the preparations were explicitly described as indistinguishable or if a double-dummy technique was used. We considered analyses adequate if all randomised patients were included in the analysis according to the intention-totreat principle. Finally, we used GRADE to describe the quality of the overall body of evidence (Guyatt 2008; Higgins 2008), defined as the extent of confidence in the estimated treatment benefits and harms.
Data synthesis
We summarised continuous outcomes using standardised mean differences (SMD), with the differences in mean values at the end of follow up across treatment groups divided by the pooled standard deviation. If differences in mean values at the end of the follow up were unavailable, we used differences in mean changes. If some of the required data were unavailable, we used approximations as previously described (Reichenbach 2007). A SMD of -0.20 standard deviation units can be considered a small difference between experimental and control group, a SMD of -0.50 a moderate difference, and -0.80 a large difference (Cohen 1988; Jüni 2006) . SMDs can also be interpreted in terms of the percent of overlap of the experimental group's scores with scores of the control group. A SMD of -0.20 indicates an overlap in the distributions of pain or function scores in about 85% of cases, a SMD of -0.50 in approximately 67%, and a SMD of -0.80 in about 53% of cases (Cohen 1988; Jüni 2006). On the basis of a median pooled SD of 2.5 cm found in large-scale osteoarthritis trials that assessed pain using a 10 cm visual analogue scale (VAS) (Nüesch 2009), SMDs of -0.20, -0.50 and -0.80 correspond to approximate differences in pain scores between experimental and control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. SMDs for function were back transformed to a standardised WOMAC disability score (Bellamy 1995) ranging from 0 to 10, on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis trials (Nüesch 2009). We expressed binary outcomes as risk ratios (RR). We used standard inverse-variance random-effects meta-analysis to combine the trials (DerSimonian 1986). We quantified heterogeneity between trials using the I 2 statistic (Higgins 2003), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance and the corresponding χ 2 test. I 2 values of 25%, 50% and 75% may be interpreted as low, moderate and high between-trial heterogeneity, although the interpretation of I 2 depends on the size and number of trials included (Rucker 2008). Then, we converted SMDs of pain intensity and function to odds ratios (Chinn 2000) to derive numbers needed to treat (NNT) to cause one additional treatment response on pain or function as compared with control, and numbers needed to harm (NNH) to cause one additional adverse outcome. We defined treatment response as a 50% improvement in scores (Clegg 2006) , which corresponds to an average decrease of 1.2 standard deviation units (Nüesch 2009). With a median standardised pain intensity at baseline of 2.4 standard deviation units and a median standardised decrease in pain scores of 0.72 standard deviation units observed in large osteoarthritis trials (Nüesch 2009), we calculated that a median of 31% of patients in the control group would achieve an improvement of pain scores of 50% or more. This percentage was used as the control group response rate to calculate NNTs for treatment response on pain. Based on the median standardised WOMAC function score at baseline of 2.7 standard deviation units and the median standardised decrease in function scores of 0.58 standard deviation units (Nüesch 2009), 26% of patients in the control group would achieve a reduction in function of 50% or more. Again, this percentage was used as the control group response rate to calculate NNTs for treatment response on function. We used median risks of 150 patients with adverse events per 1000 patient-years, four patients with serious adverse events per 1000 patient-years and 17 drop-outs due to adverse events per 1000 patient-years, observed in placebo groups in large osteoarthritis trials (Nüesch 2009), to calculate NNHs for safety outcomes. All P values are two-sided. We performed the data analysis in RevMan version 5 (RevMan 2008) and STATA version 10.1 (Stat-aCorp, College Station, Texas).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. We identified 231 references to articles and considered 37 to be potentially eligible (Figure 1 ). Five reports describing four completed trials in 656 patients met our inclusion criteria. Contacting experts and checking conference readings and trial registers did not result in the identification of additional RCTs. Three small sized trials used a two-arm parallel-group design to compare SAMe with placebo (Bradley 1994; König 1990; Montrone 1985) . A large sized multicentre study by Caruso and Pietrogrande used a three-arm parallel-group design to compare SAMe with naproxen and placebo (Caruso 1987). The trial arm involving naproxen was excluded from this review. Duration of the studies ranged from three (Montrone 1985) to 12 weeks (König 1990); follow up was at the end of trial in all studies. In all studies patients had a clinical severity requiring simple nonsurgical treatments (Jüni 2006), three trials included patient with functional classes II and Ill and definite radiological signs of osteoarthritis, but one trial included patients without typical radiographic signs (König 1990). In two trials, only patients with osteoarthritis of the knee were included (Bradley 1994; König 1990), while the trial by Montrone 1985 included both: 51 patients (67%) with knee osteoarthritis and 25 (33%) patients with hip osteoarthritis. Caruso 1987 included knee (55%), hip (24%), hand (7%) and spine osteoarthritis (14%). Despite the description of an adequately concealed randomisation with stratification for study centre, the patient population in the two centres in Bradley 1994 differed. At one site, the majority of the patients were female (85%) with an average age of 58 years and an average disease duration of 10.9 years. At the other site, only 21% of the patients were female with a average age of 63 years and an average disease duration of 12.4 years. SAMe and placebo were applied orally in all studies. However, one study started with intravenous SAMe for the first five days before switching to an oral formulation of the interventions (Bradley 1994 
Risk of bias in included studies
One study reported adequate generation of the randomisation sequence and adequate allocation concealment using coded pharmacy (Bradley 1994, Figure 2 ). The study of Caruso 1987 reported the use of block randomisation but did not report how blocks were generated, nor the method used for concealment of allocation. The other two studies were unclear about the methods used to randomise patients (König 1990; Montrone 1985).
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality
item for each included study.
All trials were described as double-blind. Three trials reported the use of indistinguishable interventions to blind patients (Bradley 1994; Caruso 1987; Montrone 1985), but only Montrone 1985 explicitly described that patients, physicians and assessors were blinded. In Bradley 1994 and Caruso 1987 only adequate blinding of patients could be assumed. The remaining study did not describe blinding of patients or physicians, nor did it describe the use of an indistinguishable placebo control (König 1990 ). None of the trials was considered to have performed an intentionto-treat analysis for any of the primary outcomes. All trials explicitly reported exclusion of randomised patients. Percentages of exclusions ranged from 5.2% to 18% in experimental groups and from 0% to 8% in control groups. One trial did not report the overall number of patients randomly allocated and the percentage of exclusions could not be determined (Bradley 1994) . Three trials failed to report the specification of a primary outcome and failed to present power calculations. The fourth trial by Bradley 1994 reported three separate pain scales as primary outcomes. Although this trial also reported a protocol based sample size calculation, it was unclear on which of the three pain outcomes the difference used in the calculation was based (Bradley 1994). Two trials were funded by a manufacturer of SAMe (Bradley 1994; Caruso 1987), whereas the source of funding was unclear in the the other two trials.
Effects of interventions
See: Summary of findings for the main comparison
Pain intensity
Two trials with two comparisons (533 patients) contributed to the meta-analysis of pain outcomes (Figure 3) . The analysis suggested a small SMD of -0.17 (95% CI -0.35 to 0.01) for pain which corresponds to a difference in pain scores of 0.4 cm on a 10 cm VAS, a difference in improvement from baseline of 8% (95% CI 0% to +15%) between SAMe and control (see 'Summary of findings for the main comparison'). An I 2 of 0% indicated the absence of between-trial heterogeneity (P for heterogeneity = 0.92), which was confirmed by visual inspection.
Figure 3. Forest plot of 2 trials comparing the effects of S-Adenosylmethionine and control (placebo or no intervention) on knee or hip pain. Values on x-axis denote standardised mean differences.
Function
Three trials (542 patients) contributed to the meta-analyses of function (Figure 4) . The analysis suggested a negligible SMD of 0.02 (95% CI -0.68 to 0.71, see 'Summary of findings for the main comparison'). An I 2 of 54% indicated a moderate degree of between-trial heterogeneity (P for heterogeneity = 0.11). On visual inspection, the variation could be explained by the trial by König 1990 that estimated an effect size favouring control. Excluding König 1990 in a sensitivity analysis, we found a SMD of -0.15 (95% CI -0.33 to 0.03), which corresponds to a difference in function scores of 0.3 units on a standardised WOMAC disability scale ranging from 0 to 10 and a difference in improvement of 6% (95% CI 0% to +13%) between SAMe and control, and a reduction of between-trial heterogeneity to 0% (P for heterogeneity = 0.11).
Figure 4. Forest plot of 3 trials comparing the effects of S-Adenosylmethionine and control (placebo or no intervention) on function. Values on x-axis denote standardised mean differences.
Safety
All trials (623 patients) contributed to the meta-analysis of patients experiencing any adverse event ( Figure 5 ). The analysis suggested a RR of 1.27 (95% CI 0.94 to 1.71). An I 2 of 0% suggested an absence of between-trial heterogeneity (P for heterogeneity = 0.39). All trials (656 patients) contributed to the meta-analysis of patients withdrawn or dropped out because of adverse events ( Figure 6 ). The analysis yielded a RR of 0.94 but confidence intervals were wide (95% CI 0.48 to 1.86). An I 2 of 0% again suggested an absence of between-trial heterogeneity (P for heterogeneity = 0.76). None of the trials contributed to the meta-analysis of patients experiencing any serious adverse event.
Figure 5. Forest plot of 4 trials comparing patients experiencing any adverse event between Sadenosylmethionine and control (placebo or no intervention). Values on x-axis denote risks ratios.
Figure 6. Forest plot of 4 trials comparing patients who withdrew because of adverse events between Sadenosylmethionine and control (placebo or no intervention).
Values on x-axis denote risks ratios.
D I S C U S S I O N
Summary of main results
Our systematic review of trials comparing S-Adenosylmethionine (SAMe) with a placebo control revealed a lack of adequately sized, methodologically sound and appropriately reported trials and a moderate degree of heterogeneity between trials reporting function outcomes, which made the interpretation of results difficult. Overall effect sizes for pain and function seemed small. We found little evidence to suggest that SAMe is unsafe, but 95% confidence intervals (CI) were wide and therefore inconclusive.
Quality of the evidence
The methodological quality and the quality of reporting in the trials was poor. All but one had small sample sizes. Insufficient information about the generation of allocation sequences and concealment of allocation was noted in three out of four randomised controlled trials. None of the trials performed analyses according to the intention-to-treat principle. All trials failed to describe serious adverse events, which is concerning. Due to the low number of trials identified, we were unable to explore the effects of dosing, route of administration, methodological quality or type of funding.
Potential biases in the review process
Our review is based on a broad literature search, and it seems unlikely that we missed relevant trials (Egger 2003). Trial selection and data extraction, including quality assessment, were done independently by two authors to minimise bias and transcription errors (Egger 2001). Components used for quality assessment are validated and reported to be associated with bias (Jüni 2001; Wood 2008). As with any systematic review, our study is limited by the quality of included trials. As indicated above, trials generally suffered from poor methodological quality, inadequate reporting and small sample size. One trial showed an unrealistically large unfavourable standardised mean difference (SMD) for function, which can best be explained by chance, as the study included only nine patients (König 1990) . Including this trial in the meta-analysis may result in a slight underestimation of the benefit of SAMe on function. We included a trial described as a double-blind study in a published letter, although the report did not specifically mention the use of randomisation. Exclusion of this study would not have altered any of our conclusions.
Agreements and disagreements with other studies or reviews
We are aware of two systematic reviews that compared the efficacy of SAMe with placebo on pain and function (Soeken 2002; Witte 2002). In line with our review, the authors did not find a statistical significant improvement in pain (SMD -0.22, 95% CI -0.69 to 0.25 in Soeken 2002; -0.38, 95% CI -0.89 to 0.12 in Witte 2002). In contrast to our conclusions, Soeken 2002 concluded that SAMe, when compared to placebo, was effective in reducing functional limitations (SMD -0.31, 95% confidence interval -0.52 to -0.10). They further concluded that the tolerability of SAMe was similar to that of placebo and greater than that of NSAIDs. The difference in conclusions regarding improvement of function can be explained by differences in outcome definitions and inclusion criteria. Soeken 2002 choose restriction in joint movement as an outcome, whereas we choose a different approach, using a hierarchy developed to minimise the impact of selective reporting of outcomes and to allow for a synthesis of evidence across different studies using divergent definitions of function. In the review of Soeken 2002, only Caruso 1987 contributed to the analysis of function, whereas we could include two additional trials (Bradley 1994 and König 1990 ). The odds ratio of 1.37 (95% CI 0.81 to 2.32) for patients experiencing adverse events in Soeken 2002 was comparable to our pooled relative ratio of 1.27 (95% CI 0.94 to 1.71).
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Routine use of S-Adenosylmethionine (SAMe) should not be recommended until further trials of adequate sample size and methodology suggest a clinically relevant effectiveness.
Implications for research
To allow unequivocal conclusions to be drawn regarding the effects of SAMe on both pain relief and function, and on safety, additional adequately powered, double-blind, placebo controlled trials should be performed. Special attention needs to be given to the use of adequate randomisation with appropriate concealment of allocation and an analysis according to the intention-to-treat principle. Although a daily intake of 1200 mg (orally) may be a reasonably effective dose with an acceptable safety profile, further clarification of the optimal dose is necessary.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bradley 1994 Analgesics other than study drugs allowed, intake assessed and found to be lower in SAMe group compared to placebo at site A, and higher in SAMe compared to placebo at site B.
Methods
Outcomes
Extracted pain outcome: pain on walking after 4 weeks, described as "walking pain" Extracted function outcome: walking disability after 4 weeks, described as "walking distance before having to stop because of knee pain" Primary outcome: > 2 reported; for HAQ pain, rest pain and walking pain Notes *In the original report the investigators presented results separately for site A and B, because the randomisation, although concealed, resulted in marked baseline differences between patients at the 2 sites with respect to demographic and disease related characteristics 
Risk of bias
Item Authors' judgement Description
Adequate sequence generation? Unclear Block randomisation was used to allocate patients, but it remained unclear how blocks were generated. Quotes: "Twentyfour patients stratified in blocks of six were expected to be enrolled from each center." and ' "Patients were allocated to one of the three treatment groups (placebo, SAMe, or naproxen) according to randomisation schedules previously established for each center."'
Allocation Reported pain outcome: pain on activities other than walking after 3 weeks, described as "weight bearing pain" Reported function outcome: composite disability scores other than WOMAC after 3 weeks, described as "pooled results from items: going upstairs and downstairs, standing up from chair, getting out of bed" No primary outcome reported
Notes
Not enough data provided for pain and function outcomes to calculate standardised mean differences and the study was therefore not included in the main analyses. We were unable to retrieve contact details of the first, second and last author of the report. Sarzi-Puttini was contacted by e-mail, but he did not reply. Further attempts by phone were unsuccessful.
Risk of bias
Item Authors' judgement Description
Adequate sequence generation? Unclear This double blind trial was published in 1985 as a short letter to the editor of Clinical Rheumatology. We assumed that treatment allocation was at random, although the letter does not specifically mention the use of randomisation.
Allocation concealment? Unclear See above
Blinding of patients? Yes The trial was described as double-blind study randomising patients to indistinguishable interventions
Blinding of physicians? Yes Physicians were blinded, as can be derived from the following quote "At the end of the treatment in double-blind conditions, both the physician and patients expressed a judgment on the overall effectiveness of the therapy".
Blinding of outcome assessors? Yes
Unclear whether extracted pain and function outcomes were recorded by patients or by physicians. However, physicians were blinded, as can be derived from the following quote "At the end of the treatment in double-blind conditions, both the physician and patients expressed a judgment on the overall effectiveness of the therapy". 
D A T A A N D A N A L Y S E S
D E C L A R A T I O N S O F I N T E R E S T
None.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Before embarking on this review, we generated a standard protocol for this, and all other Cochrane Reviews performed by our group. The protocol was approved by the Editorial Board of the Cochrane Musculoskeletal Review Group (CMSG). Due to the low number of trials included, we had to deviate from the original protocol in some aspects. We could not explore the association between trial size and treatment effects with funnel plots and could not perform stratified analyses, which were planned to evaluate if treatment effects on pain and function were affected by type of control (placebo or sham intervention versus no intervention), concealment of allocation (adequate versus inadequate or unclear), blinding of patients (adequate versus inadequate or unclear), analysis in accordance with the intention-to-treat principle (yes versus no or unclear), trial size, funding, and differences in the use of co-interventions in the trial groups. In addition, we anticipated including dosage of intervention as continuous variables at trial level. Finally, visual inspection revealed a potential outlier in the heterogeneous meta-analysis of function and we performed a sensitivity analysis excluding this outlier as required by one of the peer reviewers.
